{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/sinusitis/prescribing-information/co-amoxiclav/","result":{"pageContext":{"chapter":{"id":"0d802baf-8d25-5d8a-9c6d-b2a448983e4a","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav","depth":2,"htmlHeader":"<!-- begin field 00ffbca2-18bb-42d3-8f89-a8e800b3f8fb --><h2>Co-amoxiclav</h2><!-- end field 00ffbca2-18bb-42d3-8f89-a8e800b3f8fb -->","summary":"","htmlStringContent":"<!-- begin item e0c83ebe-005c-440f-8dde-a8e800b3f6ac --><!-- end item e0c83ebe-005c-440f-8dde-a8e800b3f6ac -->","topic":{"id":"6d2333af-675d-5bf3-8f7d-21404b5f0aa9","topicId":"251eec02-9620-4893-97bb-7a4e69e81da3","topicName":"Sinusitis","slug":"sinusitis","lastRevised":"Last revised in June 2018","chapters":[{"id":"2e4afda1-e9d5-5296-a027-01f4617ab6d0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"405b3d6d-e395-5fea-bc5e-02ddf80a8bd2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"22d307e8-3756-562c-b49a-55d20a9d0c5d","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"36290f8d-5730-5655-8fa4-0d3f584a2980","slug":"changes","fullItemName":"Changes"},{"id":"b0ba5cc8-0ed6-52d6-86c5-12833f47d8d3","slug":"update","fullItemName":"Update"}]},{"id":"f730377b-2158-527d-b9a1-e99c0653afd0","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"5f96218a-0038-5b66-8c21-7db2d19f37b7","slug":"goals","fullItemName":"Goals"},{"id":"f4318fc5-fa1f-52cc-964f-2eeb9d4f7a27","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5a355772-1fc0-5033-929c-388a6956d7f5","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"41d933ba-5f60-5f51-9a18-8d60f08747d9","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"de2c52a0-2248-5977-a8e4-e495835a4f71","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"87fd2967-db43-5938-a83c-4761cd508da1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"6b9273f7-5c2c-5994-a3d4-8617be04677e","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"62fda2cc-020c-5dda-8886-be553f1b04bc","slug":"definition","fullItemName":"Definition"},{"id":"d0ca7ab5-8889-52dd-8ac6-bcf949adf403","slug":"causes","fullItemName":"Causes"},{"id":"6c331f3e-5cee-537d-9ff6-41dba5324ae1","slug":"prevalence","fullItemName":"Prevalence"},{"id":"2b91bcbf-5ce3-5cdb-bb8d-03f4297a60fc","slug":"complications","fullItemName":"Complications"}]},{"id":"17787dc5-901a-5bd4-93f1-b3bd7830f0a8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"a3d013cf-b195-59ed-ac16-d0dc956a2637","slug":"diagnosis-acute-sinusitis","fullItemName":"Diagnosis - acute sinusitis"},{"id":"35be5a2e-61f3-5478-b238-c91020678ab0","slug":"diagnosis-chronic-sinusitis","fullItemName":"Diagnosis - chronic sinusitis"},{"id":"3ec7ffd9-5556-5eb7-9e51-14b4e1403c11","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"a5e0292f-f277-5859-bf17-fe0b4557eae3","fullItemName":"Management","slug":"management","subChapters":[{"id":"851420e1-952f-58e9-bb2d-b69ed5134584","slug":"acute-sinusitis","fullItemName":"Scenario: Acute sinusitis"},{"id":"fe33ee40-93d8-59ba-b62a-2f9ccc74cc63","slug":"chronic-sinusitis","fullItemName":"Scenario: Chronic sinusitis"}]},{"id":"ccbcf182-fe04-59e6-abdc-75557dc3c700","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"bc9974c3-e759-5746-8c96-b4538af16946","slug":"analgesia","fullItemName":"Analgesia"},{"id":"b7e24d48-87af-5f2c-9097-f4e3b1de894d","slug":"nasal-corticosteroids","fullItemName":"Nasal corticosteroids"},{"id":"5f63c8f8-0eaa-5fe0-b473-2d5e3aef00d1","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"0d802baf-8d25-5d8a-9c6d-b2a448983e4a","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"e874a37b-5cc8-58c8-9335-ac01e3b17271","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"bb4fef09-b30c-5637-ae85-ba203f26acd9","slug":"phenoxymethylpenicillin","fullItemName":"Phenoxymethylpenicillin"}]},{"id":"827f1e92-8727-5460-b9ae-00929701cc77","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4dbc93c2-6562-533b-8dd9-0891fc35822e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8b0f7242-5fbb-5eb4-8b1a-13af5d4383df","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4a3d9d72-ed21-52d6-ba45-abcfb27ec6b4","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1b69a1e4-ec7f-5483-873c-2bb4bfb1345c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f04034ff-dd83-5bf5-83de-77fe9877df85","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"f54f59b3-2893-5e4b-8dd2-3bee521cb237","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"164a0943-7f01-50bd-8c8f-a3695b72b662","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ccbcf182-fe04-59e6-abdc-75557dc3c700","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"6a27e6d1-deda-571c-9729-64943b8178c3","slug":"cautions-contraindications","fullItemName":"Cautions and contraindications","depth":3,"htmlHeader":"<!-- begin field 9ebfbad7-4431-48da-8fba-a8e800b99ad3 --><h3>Cautions and contraindications</h3><!-- end field 9ebfbad7-4431-48da-8fba-a8e800b99ad3 -->","summary":"","htmlStringContent":"<!-- begin item 7b63bebb-f238-44a7-ab16-a8e800b99994 --><!-- begin field b3ee95c2-1295-498e-8375-a8e800b99ad3 --><ul><li><strong>Do not prescribe co-amoxiclav in people with:</strong><ul><li>A <em>true </em>penicillin allergy — allergic reactions to penicillins occur in 1–10% of exposed individuals; anaphylactic reactions occur in fewer than 0.05% of treated patients.<ul><li>Gastrointestinal adverse effects alone (for example, nausea, vomiting, or diarrhoea) do <em>not </em>constitute an allergy to penicillin. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a> for more information.</li></ul></li><li>A hypersensitivity to cephalosporins — there is some evidence of partial cross-allergenicity. </li><li>A history of co-amoxiclav- or penicillin-associated jaundice or hepatic dysfunction.</li></ul></li><li><strong>Prescribe co-amoxiclav with caution in people with:</strong><ul><li>Hepatic impairment – monitor closely.</li><li>Chronic kidney disease (CKD) — reduce the dose if the estimated glomerular filtration rate (eGFR) is 30 mL/minute/1.73 m<sup>2</sup> or less.</li><li>Acute lymphocytic leukaemia, chronic lymphocytic leukaemia, cytomegalovirus infection, glandular fever — increased risk of erythematous rashes.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">BNF 75, 2018</a>]</p><!-- end field b3ee95c2-1295-498e-8375-a8e800b99ad3 --><!-- end item 7b63bebb-f238-44a7-ab16-a8e800b99994 -->","subChapters":[]},{"id":"0c42eb83-710e-5a96-9e6c-5d9b8fc25e82","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 64831cfb-4dd4-4588-abbf-a8e800b9b61c --><h3>Adverse effects</h3><!-- end field 64831cfb-4dd4-4588-abbf-a8e800b9b61c -->","summary":"","htmlStringContent":"<!-- begin item e671eb3a-d740-488d-8e5c-a8e800b9b4c5 --><!-- begin field f1ee090a-923f-4d3e-bc6f-a8e800b9b61c --><ul><li><strong>Gastrointestinal </strong>— nausea and vomiting (common), diarrhoea (very common), antibiotic associated colitis (frequency unknown).</li><li><strong>Nervous system</strong> — headache, dizziness (uncommon).</li><li><strong>Skin</strong> — skin rash, urticaria and pruritus (uncommon), drug reaction with eosinophilia and systemic symptoms (DRESS) (frequency unknown).<ul><li><strong>Rarely:</strong> erythema multiforme</li><li><strong>Frequency unknown:</strong> Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous and exfoliative dermatitis and acute generalised exanthematous pustulosis.</li></ul></li><li><strong>Other rare, or very rare adverse effects, or those for which the freqency is not known include:</strong><ul><li>Hepatitis, cholestatic jaundice.</li><li>Convulsions.</li><li>Hypersensitivity reactions (serious and occasionally fatal).  </li><li>Interstitial nephritis.</li><li>Leucopenia, thrombocytopenia, haemolytic anaemia.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">BNF 75, 2018</a>]</p><!-- end field f1ee090a-923f-4d3e-bc6f-a8e800b9b61c --><!-- end item e671eb3a-d740-488d-8e5c-a8e800b9b4c5 -->","subChapters":[]},{"id":"8ffc706a-2e35-573c-9917-d42473328e18","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field b4b53f83-3fb7-4725-b4b5-a8e800b9d3f0 --><h3>Drug interactions</h3><!-- end field b4b53f83-3fb7-4725-b4b5-a8e800b9d3f0 -->","summary":"","htmlStringContent":"<!-- begin item 7f981e42-a1b3-4339-83b9-a8e800b9d295 --><!-- begin field bf41cb1e-36ac-4094-b48b-a8e800b9d3f0 --><ul><li><strong>Allopurinol </strong>— concomitant use of allopurinol and amoxicillin may increase the incidence of skin rashes.</li><li><strong>Methotrexate </strong>— co-amoxiclav may reduce methotrexate clearance, causing an increased risk of toxicity.<ul><li>Monitor methotrexate levels more closely. One recommendation is to carry out twice weekly platelet and white cell counts for 2 weeks initially, with the measurement of methotrexate levels if toxicity is suspected. </li></ul></li><li><strong>Mycophenolate mofitil</strong> — reduction in the level of active metabolite may occur when given with co-amoxiclav.</li><li><strong>Oral anticoagulants (warfarin, phenindione)</strong> — prolongation of international normalised ratio has been reported in people taking penicillins and warfarin concurrently.<ul><li>Monitor the prothrombin time or international normalized ratio (INR) more closely with the addition or withdrawal of a penicillin. Adjustment of the anticoagulant dose may be necessary.</li></ul></li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of co-amoxiclav.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>Probenecid </strong>— concomitant administration may result in increased levels of amoxicillin, but not clavulanic acid.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">FSRH, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">BNF 75, 2018</a>]</p><!-- end field bf41cb1e-36ac-4094-b48b-a8e800b9d3f0 --><!-- end item 7f981e42-a1b3-4339-83b9-a8e800b9d295 -->","subChapters":[]},{"id":"06019b5f-5cce-5db9-9a88-be48024dd4e6","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 3ec4f51b-0d03-4c79-952d-a8e800b9f087 --><h3>Pregnancy and breastfeeding</h3><!-- end field 3ec4f51b-0d03-4c79-952d-a8e800b9f087 -->","summary":"","htmlStringContent":"<!-- begin item dc0ac768-df81-4e0e-9220-a8e800b9efca --><!-- begin field c2be934a-830b-4164-ae62-a8e800b9f087 --><h4>Pregnancy</h4><ul><li>Co-amoxiclav is not known to be harmful in pregnancy, but the manufacturer advises avoidance of use during pregnancy unless considered essential.</li></ul><h4>Breastfeeding</h4><ul><li>Trace amounts of co-amoxiclav are found in breastmilk and it may cause diarrhoea or fungal infection of mucous membranes in the infant.<ul><li>Penicillins (and cephalosporins) are the antibiotics of choice in women who are breastfeeding.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">Kearney, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">BNF 75, 2018</a>]</p><!-- end field c2be934a-830b-4164-ae62-a8e800b9f087 --><!-- end item dc0ac768-df81-4e0e-9220-a8e800b9efca -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}